Semaglutide results timeline: how long Wegovy really takes to work

The most common question about semaglutide (sold for weight management as Wegovy) is some version of “how fast does it work?” The honest answer is that it works gradually, and on a schedule that is deliberately slow. In the pivotal trial, the average participant lost about 14.9% of body weight — but that figure is measured at 68 weeks, not at one month.^[1] Understanding why the curve is slow, and what a realistic trajectory looks like, is the difference between staying the course and quitting in week three because the scale has barely moved.

The dose ladder is the timeline

You cannot understand the results timeline without understanding the dosing schedule, because they are the same thing. Wegovy is not started at its full dose. The FDA-approved escalation climbs over at least 16 weeks through five steps — 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg, and finally the 2.4 mg maintenance dose, each held for four weeks before moving up.^[2]For roughly the first four months you are, by design, mostly below the dose that produced the headline trial result.

Why so slow? The titration exists for tolerability, not caution for its own sake. Ramping the dose gradually is how the regimen blunts the nausea, and other gastrointestinal effects that come with starting a GLP-1 receptor agonist; the label explicitly frames the schedule as a way to reduce the likelihood of these effects.^[2] If you want the mechanics of how those side effects rise and fade, our GLP-1 GI side-effect timeline walks through it. The practical takeaway: the slow ramp is also what makes the early weeks feel underwhelming on the scale.

What a realistic trajectory looks like

In the first days to weeks, the change most people notice is not the scale — it is appetite. Reduced hunger, smaller portions, and earlier fullness are the early appetite-suppressing signals of GLP-1 action, and they can show up well before meaningful weight loss does. Treat these as the leading indicator that the drug is doing something; the weight follows later.

Over the first few months, as the dose climbs, visible weight loss accrues. But this is a steady drip, not a drop — loss measured in fractions of a pound to a couple of pounds a week for many people, building cumulatively. The curve in the pivotal trial was still descending well past the halfway mark and only began to plateau later in the 68-week window.^[1] In other words, the biggest numbers arrive after many months of consistency, not in the honeymoon weeks.

At the 68-week endpoint, STEP 1 reported a mean change in body weight of roughly −14.9% on semaglutide 2.4 mg, versus about −2.4% on placebo, in adults with overweight or obesity who also received lifestyle support.^[1] That is a large average effect for a weight-management medication — and it is an average, which is the next thing to internalize.

Results vary widely — that 14.9% is a mean

A trial mean hides an enormous spread. In STEP 1, a large share of participants lost 15% or even 20% of their body weight, while others lost much less; the response is genuinely heterogeneous.^[1]Your starting weight, your dose tolerance, whether you reach and hold 2.4 mg, and the lifestyle changes layered on top all move your personal number. No one can promise you a specific result, and any source that does is misrepresenting how this drug behaves. The right framing is a probability distribution, not a guarantee.

Semaglutide is also the lower-tier molecule in its own family in terms of average weight loss; if you are comparing options, our overview of the semaglutide weight-loss trials and the Ozempic versus Wegovy evidence breakdown put the numbers side by side.

What happens when you stop

This is the part the marketing tends to skip. Semaglutide controls weight while you take it; it does not reset a set point. The STEP 4 withdrawal trial put numbers on this directly: participants ran in on semaglutide for 20 weeks, then were randomized either to continue or to switch to placebo. The group that stopped the drug regained a substantial portion of the lost weight over the following year, while those who continued kept losing.^[3] The clinical implication is blunt — for most people this is an ongoing treatment, and an exit plan (or its absence) should be part of the decision from day one, not an afterthought.

Managing expectations honestly

Put together, the timeline looks like this: appetite changes within weeks, a slow and titration-paced weight-loss curve over the first few months, the bulk of the average effect accumulating across most of a year, wide individual variation around that average, and weight regain likely if treatment stops. None of that is a reason to be discouraged — a sustained ~15% average loss is clinically meaningful — but it is a reason to enter with the right time horizon. People who quit at four to eight weeks because they expected a dramatic early drop are quitting before the drug has even reached its working dose.

One more honest caveat on what the scale is measuring: a meaningful fraction of GLP-1 weight loss is lean mass, not just fat, which is why resistance training and adequate protein matter alongside the drug. We cover that trade-off in GLP-1 and lean-mass loss. The goal is not the fastest number on the scale — it is a slower, more durable, better-composed result.

This article is educational and not medical advice. Semaglutide is a prescription medication; dosing, suitability, and what to expect should be decided with a licensed clinician. Figures cited are trial averages and do not predict any individual’s results.